Findings from REDUCE-IT are the first to show that EPA lowers the relative risk of hard cardiovascular endpoints. Johns Hopkins' Seth Martin, MD, and colleagues put the trial in perspective.
Cardiorenal syndrome has 5 subtypes that are each sbudivided as well. This quiz focuses on type 4--so cardiologists and nephrologists, unite!
Fish oil or fish for CV protection? It's a well studied yet unresolved question. Highlights, here, of the ASCEND study and all those that came before.
Patients with renal disease are poorly represented in studies of treatment for STEMI but, a new study finds, are at much greater risk for MACE and death.
Either one is fine – the point is to make sure the practice stays a step ahead of the next new drug class causing the problem.
Salt sensitivity of blood pressure (SSBP) is still poorly understood. How much do you know about it? Find out, here.
ECG Challenge: A 72-year-old woman is seen with generalized weakness x1week, acute altered mental status, and polydipsia. What's your ECG read?
Have results of the COMPASS trial (rivaroxaban + aspirin in stable CAD) changed your opinion or clinical use of anticoagulants in patients post-ACS? If so, how?
Hypertension is recognized as the most important risk factor for heart failure with preserved ejection fraction. Please, treat to target!
Obstructive sleep apnea negatively impacts lipid levels, greatly increasing risk for CV disease and independent of obesity, according to the largest analysis of the link to date.